Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $124.15 Average Price Target from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have received a consensus rating of “Hold” from the twenty-two research firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $124.15.

Several equities research analysts have issued reports on ZBH shares. Stifel Nicolaus raised their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Raymond James dropped their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Barclays decreased their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research note on Monday, February 10th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.95% of the company’s stock.

Hedge Funds Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently made changes to their positions in ZBH. Franklin Resources Inc. lifted its position in shares of Zimmer Biomet by 398.7% in the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider’s stock worth $369,469,000 after purchasing an additional 2,796,372 shares during the period. Norges Bank bought a new stake in Zimmer Biomet during the fourth quarter valued at $216,223,000. Dodge & Cox grew its holdings in Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider’s stock worth $2,019,480,000 after acquiring an additional 2,044,645 shares during the period. Nuveen Asset Management LLC lifted its stake in shares of Zimmer Biomet by 191.8% in the 4th quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider’s stock valued at $146,763,000 after purchasing an additional 913,310 shares during the period. Finally, Sound Shore Management Inc. CT bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at about $81,447,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $97.90 on Tuesday. Zimmer Biomet has a 12-month low of $96.58 and a 12-month high of $123.96. The firm has a market capitalization of $19.37 billion, a price-to-earnings ratio of 22.00, a P/E/G ratio of 1.95 and a beta of 0.84. The stock’s 50 day moving average price is $105.95 and its two-hundred day moving average price is $106.78. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the business posted $2.20 earnings per share. On average, analysts anticipate that Zimmer Biomet will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.98%. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.